Empire Eye and Laser Center actively participates in several US Food and Drug Administration Phase III and Phase IV trials and studies. We have a special, standardized, and calibrated exam lane for our research evaluations. Directed by Dr. Daniel Chang, our participation premarket approval investigations means that our patients uniquely have access to technologies that may be years away for patients in the United States. The goal of all of these studies is safer and better outcomes for our patients.

Current projects include work in the following areas:

  • Visual outcomes, functional outcomes, and patient satisfaction in patients with multifocal IOLs
  • Improving IOL refractive outcomes with multiple repeated biometry measurements
  • Intraoperative and postoperative alignment and centration of IOLs
  • Investigating next generation multifocal IOL technology

Being a patient at Empire Eye and Laser Center means that you have access to the very best medical and surgical eye care that is currently available.

Here is a list of past and current clinical research studies at Empire Eye and Laser Center. If you are interested in participating in clinical research, please call our office at 661-325-3937 and ask for Jacque, our Research Coordinator.

Past Research Studies

Ocular Therapeutix – Dexamethasone PUnctum Plug Study 2014 – Principle Investigator

Phase 3, multicenter, randomized, double-masked and placebo-controlled study evaluating the safety and efficacy of a dexamethasone punctum plug for the control of post operative inflammation and pain after routine cataract surgery.

SARcode Bioscience – OPUS II 2013 – Principal Investigator

Phase 3, multicenter, randomized, double-masked and placebo-controlled study evaluating the safety of a 5.0% concentration of Lifitegrast Ophthalmic Solution compared to placebo in subjects with Dry Eye currently using Artificial Tears (OPUS-2).

Valeant Pharmaceuticals -CeraVe 2013 – Principal Investigator

A single center, open label study to evaluate the ophthalmologic effects on subjects who have CeraVe Eye Repair Cream applied around the periorbital skin.  Pre-Launch phase.

FERA Pharmaceuticals – Investigator Initiated Trial, 2013 – Sub-Investigator

Randomized, investigator-masked evaluation in a 1:1 fashion to Hydrocortisone Ophthalmic Ointment 0.5% or placebo (same vehicle used to make Hydrocortisone Ophthalmic Ointment).

SARcode Bioscience – SONATA 2012 – Principal Investigator

A Phase 3, multicenter, randomized, double-masked and placebo-controlled study evaluating the safety of a 5.0% concentration of Lifitegrast Ophthalmic Solution compared to placebo in subjects with Dry Eye (SONATA).

EyeVis – “ONIT” – ORAL NUTRITION IMPACT ON TEAR FILM 2012 – Sub-Investigator

The eight week feasibility study is to determine if subjects presenting with dry eye with confirmed reduction of four out of seven diagnostic markers and symptoms respond to nutritional therapy.

Tear Lab – A POST-MARKET OSMOLARITY PREVALENCE STUDY FOR TEARLAB OSMOLARITY SYSTEM 2011 – Sub-Investigator

The primary objective of this study is to determine overall prevalence of normal and abnormal tear fluid osmolarity in the patient population of clinicians who use the TearLab Osmolarity System when used within its FDA 510(k) cleared product labeling (FDA k083184)